Stone Ridge Asset Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Stone Ridge Asset Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,707	Closed	-$568K	–	956
2019 Q3	$568K	Hold	1,707	–	–	0.03%	635
2019 Q2	$534K	Hold	1,707	–	–	0.03%	694
2019 Q1	$522K	Hold	1,707	–	–	0.03%	700
2018 Q4	$396K	Hold	1,707	–	–	0.02%	882
2018 Q3	$534K	Hold	1,707	–	–	0.03%	814
2018 Q2	$493K	Hold	1,707	–	–	0.03%	796
2018 Q1	$427K	Hold	1,707	–	–	0.02%	866
2017 Q4	$407K	Buy	+1,707	New	+$414K	0.03%	915

Other funds holding BIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Stone Ridge Asset Management's BIO Position: Q4 2019 in Review

Stone Ridge Asset Management sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2019, closing a stake of 1,707 shares — an estimated $568K sold.

Stone Ridge Asset Management first reported a position in BIO in Q4 2017 and held it in 8 quarters. The position peaked at $568K in Q3 2019. 387 funds tracked by Wall St. Rank hold BIO as of Q4 2019.

Stone Ridge Asset Management reported no remaining Bio-Rad Laboratories Class A position as of Q4 2019 after selling out during the quarter.
Stone Ridge Asset Management sold 1,707 Bio-Rad Laboratories Class A shares in Q4 2019, an estimated $568K.
Stone Ridge Asset Management first reported a position in Bio-Rad Laboratories Class A in Q4 2017 and held it in 8 quarters.
Stone Ridge Asset Management's Bio-Rad Laboratories Class A position peaked at $568K in Q3 2019.
387 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2019.

Based on Stone Ridge Asset Management's 13F filing for Q4 2019, filed 6 Feb 2020.